FRLI - Frelii, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1200
+0.0300 (+33.33%)
As of 2:15PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0900
Open0.0700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0700 - 0.1200
52 Week Range0.0200 - 2.7450
Volume14,025
Avg. Volume21,237
Market Cap6.416M
Beta (5Y Monthly)-9.80
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Frelii Provides Update on GATC Canna Revenue Sharing Agreement

    Multiple acquisitions to drive significant growth of customer base LEHI, UT / ACCESSWIRE / February 14, 2020 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology ...

  • ACCESSWIRE

    Frelii Announces International License and Profit Sharing Agreement

    Under the terms of the Agreement, Genecor AI Inc., a Canadian Company, has acquired the International rights (excluding the USA), to Frelii's patent pending AI, Navii for $750,000 payable in installments over 3 months. Through its network of medical professionals, Genecor AI will market Frelii's DNA technology in Canadian market, with plans to expand to other jurisdictions.

  • ACCESSWIRE

    Frelii Announces Master License Agreement with Systemic Formulations

    LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a Master License Agreement ("Agreement) with Systemic Formulations Inc. ("Customer"). "We believe the efficacy of our genome discovery artificial intelligence, Navii, has been further validated today, as trusted leading nutraceutical company Systemic Formulations has begun selling DNA kits to its network of healthcare practitioners using Navii to provide market leading analysis," stated Frelii CEO, Ian Jenkins.

  • ACCESSWIRE

    Frelii Announces Shareholder Update

    LEHI, UT / ACCESSWIRE / October 30, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or "the Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update to shareholders regarding technology and marketing advancements. Frelii's CEO, Ian Jenkins stated, "Over the past year, through the diligence of our development team, led by respected industry leader Jayson Uffens, the Company has successfully navigated a variety of challenges, resulting in critical enhancements to our technology offering. The Company utilizes artificial intelligence and whole genome analysis to increase patient outcomes and reduce direct costs.

  • OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
    PR Newswire

    OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May

    NEW YORK , June 5, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...